- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02318758
Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers (TDE-PH-125)
Randomized, Single Dose, 4-Way Cross-over Study to Investigate the Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers
Study Overview
Detailed Description
This study will compare the effects of ethanol on the PKs of a 1 mg dose of UT-15C in healthy volunteers to determine the in vivo effects of ethanol, including the timing of ethanol consumption in relation to UT-15C ingestion.
This is an open-label, randomized, single-center, four-way (period), crossover study in which 28 healthy volunteers will receive a single 1 mg oral dose of UT-15C and/or ethanol. Eligible subjects will be randomly assigned to one of four treatment sequences such that all subjects will receive all four sequences in a pre-specified order.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- PPD International
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject voluntarily gives informed consent to participate in the study.
- Women of child bearing potential includes any female who has experienced menarche and who has not undergone successful surgical sterilization. Women of childbearing potential must practice true abstinence from intercourse when it is in line with their preferred and usual lifestyle, or use two different forms of highly effective contraception for the duration of the study, and for at least 30 days after discontinuing study medication. Medically acceptable forms of effective contraception include: (1) approved hormonal contraceptives (such as birth control pills), (2) barrier methods used with a spermicide, (3) an intrauterine device, or (4) partner vasectomy. For women of childbearing potential, a negative urine pregnancy test is required at Screening and Baseline prior to initiating study medication.
- The subject, if male, must use a condom during the length of the study, and for at least 48 hours after discontinuing study medication.
- Healthy male and female subjects aged 21-55 years of age at the time of signing the informed consent.
- Weight between 55 and 100 kg, with a BMI between 19.0-29.9 kg/m2, inclusive for female subjects and weight between 55 and 120 kg, with a BMI between 19.0-32.0 kg/m2, inclusive for male subjects.
- Regular consumption of ethanol with no recent changes in pattern of consumption
- In the opinion of the Principal Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing and likely to be cooperative with protocol requirements, including attending all study visits.
Exclusion Criteria:
- The subject is pregnant or lactating.
- Subject has any clinically relevant abnormality identified during the screening physical examination, 12-lead ECG, or laboratory examinations.
- Subject has a history of anaphylaxis, a previous documented hypersensitivity reaction, or a clinically significant idiosyncratic reaction to any drug.
- Subject has a clinically significant history of neurological, cardiovascular, respiratory, endocrine, hematological, hepatic, renal, gastrointestinal, genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a psychiatric disorder, or any other chronic disease, whether controlled by medication or not.
- Subject has a history of postural hypotension, or unexplained syncope.
- Subject has a blood pressure that is less than 85 mmHg systolic or 50 mmHg diastolic at Screening or Baseline.
- Subject has a pulse rate that is greater than 90 bpm after sitting at rest for 5 minutes at Screening or Baseline.
- Subject has a blood pressure that is greater than 150 mmHg systolic or 90 mmHg diastolic at Screening or Baseline.
- Subject has a predisposing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs.
- Subject has tested positive at the screening visit for HIV infection, HBsAg, or the HCV antibody.
- Subject currently uses tobacco products or has a history of tobacco use within two months prior to Baseline.
- Subject has a history of ethanol abuse or a history of or current impairment of organ function reasonably related to ethanol abuse.
- Subject has a history of or current evidence of abuse of licit or illicit drugs, including a positive urine screen for drugs of abuse at Screening or Baseline.
- Subject has a history of abnormal bleeding tendencies.
- Subject has donated blood or plasma or has lost a significant volume of blood within four weeks prior to Baseline.
- Subject has clinically significant abnormal laboratory values in the opinion of the treating Investigator.
- Subject has participated in a research study within the last 30 days.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Comparison 1
UT-15C 1 mg alone
|
sustained release oral treprostinil
Other Names:
|
Active Comparator: Comparison 2
UT-15C 1 mg plus ethanol (simultaneously)
|
sustained release oral treprostinil
Other Names:
Absolut 100 vodka
Other Names:
|
Active Comparator: Comparison 3
UT-15C 1 mg administered 1 hour before ethanol
|
sustained release oral treprostinil
Other Names:
Absolut 100 vodka
Other Names:
|
Active Comparator: Comparison 4
UT-15C 1 mg administered 1 hour after ethanol
|
sustained release oral treprostinil
Other Names:
Absolut 100 vodka
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics (PK) of oral treprostinil (Cmax)
Time Frame: Subjects will be enrolled for 24 days
|
Subjects will be enrolled for 24 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability via laboratory values, collection of adverse events, vital signs and electrocardiogram.
Time Frame: Subjects will be enrolled for 24 days
|
Subjects will be enrolled for 24 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TDE-PH-125
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on UT-15C
-
United TherapeuticsWithdrawnPulmonary HypertensionUnited States, Australia, Mexico
-
United TherapeuticsCompleted
-
United TherapeuticsCompletedPulmonary Arterial Hypertension | Hypertension, PulmonaryUnited States
-
United TherapeuticsCompletedPulmonary HypertensionUnited States, Canada, Germany, Spain, Belgium, Sweden, Israel, France, Italy, Netherlands, Portugal, United Kingdom
-
United TherapeuticsCompletedPulmonary Arterial Hypertension | Hypertension, PulmonaryUnited States
-
United TherapeuticsCompletedAn Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionKorea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
-
United TherapeuticsCompleted
-
United TherapeuticsCompletedPulmonary Arterial HypertensionKorea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
-
United TherapeuticsCompletedPulmonary Arterial Hypertension | Renal DysfunctionUnited States